…
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Palisade Bio Inc (NASDAQ: PALI) is a clinical-stage biopharmaceutical company developing therapeutic candidates and advancing programs through clinical development toward potential regulatory approval. Long-term growth drivers may include clinical trial progress, favorable regulatory outcomes, strategic partnerships and eventual commercialization, and investors may find the company attractive for potential upside if its programs address unmet medical needs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -16.78M | -14.44M | -12.30M | -14.26M | -26.62M |
| Net income | -16.78M | -14.44M | -12.30M | -12.80M | -27.27M |
| Selling general administrative | 7.86M | 5.80M | 6.20M | 8.76M | 9.31M |
| Selling and marketing expenses | - | - | 0.00M | - | - |
| Gross profit | -0.00M | -0.00M | 0.25M | - | - |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Ebit | -16.77M | -14.43M | -12.29M | -15.72M | -41.85M |
| Ebitda | -16.77M | -14.42M | -12.28M | -15.15M | -44.28M |
| Depreciation and amortization | 0.00M | 0.00M | 0.00M | 0.57M | -2.43M |
| Operating income | -18.06M | -14.86M | -13.07M | -15.72M | -41.85M |
| Other operating expenses | 18.06M | 14.86M | 13.32M | 15.31M | 41.85M |
| Interest expense | 0.01M | 0.01M | 0.01M | 0.01M | 2.40M |
| Net interest income | -0.01M | -0.01M | -0.01M | -0.01M | -3.08M |
| Income tax expense | - | - | 0.02M | -1.46M | 0.66M |
| Total revenue | 0.00M | 0.00M | 0.25M | 0.00M | 0.00M |
| Total operating expenses | 18.06M | 14.86M | 13.32M | 15.31M | 41.85M |
| Cost of revenue | 0.00M | 0.00M | 0.00M | - | - |
| Total other income expense net | 1.27M | 0.42M | 0.77M | 1.46M | 15.24M |
| Net income from continuing ops | -16.78M | -14.44M | -12.30M | -14.26M | -26.62M |
| Net income applicable to common shares | - | - | - | -14.55M | -26.62M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 134.34M | 10.88M | 14.05M | 15.76M | 12.51M |
| Other current assets | 0.57M | 0.65M | 0.64M | 2.35M | 1.88M |
| Total liab | 4.96M | 3.39M | 2.74M | 3.28M | 5.15M |
| Total stockholder equity | 129.38M | 7.49M | 11.31M | 12.48M | 7.37M |
| Other current liab | 3.80M | 1.85M | 1.61M | 0.99M | 0.78M |
| Common stock | 1.59M | 0.03M | 0.09M | 0.03M | 0.14M |
| Capital stock | 1.60M | 0.03M | 0.10M | 0.03M | 0.14M |
| Retained earnings | -152.72M | -135.94M | -121.51M | -109.19M | -94.64M |
| Other liab | - | - | - | - | 2.65M |
| Other assets | - | - | - | - | 0.03M |
| Cash | 133.38M | 9.82M | 12.43M | 12.38M | 10.49M |
| Total current liabilities | 4.64M | 3.24M | 2.59M | 3.01M | 2.50M |
| Net debt | -133.31M | -9.65M | -12.06M | -11.98M | -10.30M |
| Short term debt | 0.07M | 0.17M | 0.28M | 0.19M | 0.20M |
| Short long term debt | 0.07M | 0.08M | 0.16M | 0.09M | 0.09M |
| Short long term debt total | 0.07M | 0.17M | 0.37M | 0.40M | 0.20M |
| Other stockholder equity | 280.51M | 143.41M | 132.72M | 121.64M | 101.86M |
| Property plant equipment | - | - | - | - | 0.11M |
| Total current assets | 134.22M | 10.49M | 13.22M | 14.73M | 12.37M |
| Net tangible assets | - | - | - | - | 7.36M |
| Net receivables | 0.26M | 0.02M | 0.15M | 1.44M | 0.15M |
| Inventory | - | 0.01M | - | -1.44M | -0.15M |
| Accounts payable | 0.77M | 1.21M | 0.70M | 1.83M | 1.52M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non currrent assets other | 0.07M | 0.27M | 0.60M | 0.72M | 0.03M |
| Non current assets total | 0.12M | 0.36M | 0.84M | 1.03M | 0.14M |
| Capital lease obligations | 0.00M | 0.09M | 0.21M | 0.32M | 0.11M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | -0.00M | -0.01M | -0.05M |
| Change to liabilities | - | - | - | - | -2.40M |
| Total cashflows from investing activities | - | - | -0.00M | - | -0.05M |
| Net borrowings | -0.32M | -0.43M | -0.39M | - | -0.18M |
| Total cash from financing activities | 134.44M | 9.58M | 11.19M | 15.26M | 24.61M |
| Change to operating activities | - | - | - | - | -2.44M |
| Net income | -16.78M | -14.44M | -12.30M | -14.26M | -26.62M |
| Change in cash | 123.59M | -2.61M | 0.05M | 1.89M | 9.78M |
| Begin period cash flow | 9.85M | 12.46M | 12.41M | 10.52M | 0.74M |
| End period cash flow | 133.44M | 9.85M | 12.46M | 12.41M | 10.52M |
| Total cash from operating activities | -10.85M | -12.19M | -11.13M | -13.36M | -14.77M |
| Issuance of capital stock | 128.22M | 8.44M | 9.42M | 14.40M | 25.11M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to account receivables | - | - | - | - | 0.08M |
| Sale purchase of stock | 0.02M | 0.01M | 0.02M | - | - |
| Other cashflows from financing activities | -0.49M | 1.57M | 2.16M | 1.65M | 20.83M |
| Change to netincome | - | - | - | - | 14.26M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.01M | 0.00M |
| Change in working capital | 1.64M | 1.39M | 0.40M | 1.25M | -4.76M |
| Stock based compensation | 3.96M | 0.65M | 0.62M | 1.03M | 1.89M |
| Other non cash items | 0.34M | 0.20M | 0.14M | -1.39M | 34.77M |
| Free cash flow | -10.85M | -12.19M | -11.14M | -13.37M | -14.77M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PALI Palisade Bio Inc |
-0.09 9.24% |
0.84 | 3.15 | - | 702.31 | 2.93 | 448.71 | 0.57 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
4600 South Syracuse Street, Denver, CO, United States, 80237
858 704 4900
14
| Name | Title | Year Born |
|---|---|---|
| Mr. J. D. Finley | Interim CEO & CFO | 1957 |
| Ms. Sharon McBrayer | Director of Operations | NA |
| Mr. Robert C. McRae | Sr. VP of Operations & Strategic Devel. | NA |
| Dr. Herbert B. Slade FAAAAI, M.D. | Chief Medical Officer | NA |
| Mr. Ryker Willie | VP of Fin. & Corp. Controller | NA |
| Mr. J. D. Finley | CEO, CFO & Director | 1958 |
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | COO & Chief Medical Officer | 1978 |
| Mr. Ryker Willie | Senior VP of Finance & Corporate Controller | NA |
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | President & Chief Medical Officer | 1977 |
| Mr. Ramesh C. Donthamsetty | Head of Corporate Development & Investor Relations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.